Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Evolus Inc (EOLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 700,967
  • Shares Outstanding, K 27,275
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,480 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.77
  • Number of Estimates 3
  • High Estimate -0.47
  • Low Estimate -1.23
  • Prior Year -0.30
  • Growth Rate Est. (year over year) -156.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.20 +10.78%
on 03/18/19
29.50 -12.88%
on 03/04/19
+1.04 (+4.22%)
since 02/21/19
3-Month
10.22 +151.47%
on 12/24/18
30.25 -15.04%
on 02/11/19
+15.13 (+143.14%)
since 12/21/18
52-Week
6.75 +280.74%
on 04/30/18
39.50 -34.94%
on 06/07/18
+13.84 (+116.69%)
since 03/21/18

Most Recent Stories

More News
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

AIMT : 22.07 (+4.35%)
EOLS : 25.70 (+2.35%)
EW : 192.15 (+1.72%)
EXAS : 92.02 (+1.70%)
AGN : 153.53 (-0.09%)
Evolus Announces Publication of U.S. Phase III Pivotal Trial Results for Jeuveau(TM) in Dermatologic Surgery

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the publication of the U.S. Phase III pivotal trial...

EOLS : 25.70 (+2.35%)
NASH, Allergies and Beauty Stocks: Invest or Not?

There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

AIMT : 22.07 (+4.35%)
EOLS : 25.70 (+2.35%)
EW : 192.15 (+1.72%)
EXAS : 92.02 (+1.70%)
AGN : 153.53 (-0.09%)
Evolus Reports Fourth Quarter and Full Year 2018 Results

Received U.S. FDA Approval of Jeuveau(TM) on February 1, 2019

EOLS : 25.70 (+2.35%)
Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the closing of a $100 million senior debt facility...

EOLS : 25.70 (+2.35%)
Evolus to Release Fourth Quarter and Full Year 2018 Financial Results and Provide a Business Update on Monday, March 18, 2019

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will release fourth quarter and full year...

EOLS : 25.70 (+2.35%)
Implied Volatility Surging for Evolus (EOLS) Stock Options

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

EOLS : 25.70 (+2.35%)
Evolus Appoints Crystal Muilenburg as Vice President Corporate Communications & Public Relations

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on delivering breakthrough products, today announced the appointment of Crystal Muilenburg as Vice President, Corporate Communications...

EOLS : 25.70 (+2.35%)
Allergan Responds to Investor's Call for CEO/Chair Role Split

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

EOLS : 25.70 (+2.35%)
LLY : 128.31 (+0.12%)
AGN : 153.53 (-0.09%)
TEVA : 17.08 (+1.30%)
Cancer Drug Development Shows That Government and Private Sector can Work Together

Considering that yesterday, February 4, was World Cancer Day, it is encouraging that the private sector and the U.S. government are mutually trying to solve a serious problem and are in fact, working closely...

EOLS : 25.70 (+2.35%)
AGEN : 2.98 (+2.76%)
TTNP : 1.88 (-6.00%)
QGEN : 40.33 (+0.80%)
MBRX : 1.33 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade EOLS with:

Business Summary

Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus,...

See More

Key Turning Points

2nd Resistance Point 26.75
1st Resistance Point 26.22
Last Price 25.70
1st Support Level 24.75
2nd Support Level 23.81

See More

52-Week High 39.50
Fibonacci 61.8% 26.99
Last Price 25.70
Fibonacci 50% 23.13
Fibonacci 38.2% 19.26
52-Week Low 6.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar